• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大规模平行筛选噬菌体文库以生成人类免疫调节单克隆抗体库。

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.

机构信息

a Department of Molecular Medicine and Medical Biotechnology , University of Naples "Federico II" , Napoli ( NA ), Italy.

b CEINGE - Biotecnologie Avanzate s.c. a.r.l ., Naples , Italy.

出版信息

MAbs. 2018 Oct;10(7):1060-1072. doi: 10.1080/19420862.2018.1496772. Epub 2018 Aug 1.

DOI:10.1080/19420862.2018.1496772
PMID:29995563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6204801/
Abstract

Immune checkpoints are emerging as novel targets for cancer therapy, and antibodies against them have shown remarkable clinical efficacy with potential for combination treatments to achieve high therapeutic index. This work aims at providing a novel approach for the generation of several novel human immunomodulatory antibodies capable of binding their targets in their native conformation and useful for therapeutic applications. We performed a massive parallel screening of phage libraries by using for the first time activated human lymphocytes to generate large collections of single-chain variable fragments (scFvs) against 10 different immune checkpoints: LAG-3, PD-L1, PD-1, TIM3, BTLA, TIGIT, OX40, 4-1BB, CD27 and ICOS. By next-generation sequencing and bioinformatics analysis we ranked individual scFvs in each collection and identified those with the highest level of enrichment. As a proof of concept of the quality/potency of the binders identified by this approach, human IgGs from three of these collections (i.e., PD-1, PD-L1 and LAG-3) were generated and shown to have comparable or better binding affinity and biological activity than the clinically validated anti-PD-1 mAb nivolumab. The repertoires generated in this work represent a convenient source of agonistic or antagonistic antibodies against the 'Checkpoint Immunome' for preclinical screening and clinical implementation of optimized treatments.

摘要

免疫检查点正在成为癌症治疗的新靶点,针对这些靶点的抗体显示出显著的临床疗效,具有与联合治疗相结合以实现高治疗指数的潜力。本工作旨在提供一种新方法,用于产生几种能够以天然构象结合其靶标的新型人免疫调节抗体,这些抗体可用于治疗应用。我们首次使用激活的人淋巴细胞对噬菌体文库进行了大规模平行筛选,以生成针对 10 种不同免疫检查点的大量单链可变片段(scFvs)的集合:LAG-3、PD-L1、PD-1、TIM3、BTLA、TIGIT、OX40、4-1BB、CD27 和 ICOS。通过下一代测序和生物信息学分析,我们对每个集合中的单个 scFv 进行了排序,并确定了那些富集程度最高的 scFv。作为通过这种方法鉴定的结合物的质量/效力的概念验证,从这三个集合(即 PD-1、PD-L1 和 LAG-3)中的三个集合中生成了人 IgG,并证明它们具有可比或更好的结合亲和力和生物学活性比临床验证的抗 PD-1 mAb nivolumab。本工作中生成的文库代表了针对“检查点免疫组”的激动剂或拮抗剂抗体的方便来源,可用于优化治疗的临床前筛选和临床实施。

相似文献

1
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.大规模平行筛选噬菌体文库以生成人类免疫调节单克隆抗体库。
MAbs. 2018 Oct;10(7):1060-1072. doi: 10.1080/19420862.2018.1496772. Epub 2018 Aug 1.
2
[Next generation of anti-immune checkpoints antibodies].下一代抗免疫检查点抗体
Med Sci (Paris). 2019 Dec;35(12):966-974. doi: 10.1051/medsci/2019193. Epub 2020 Jan 6.
3
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.通过快速降低抗原浓度和使用流式细胞术筛选酵母文库,快速获得新型抗 PD-L1 抗体的亲和力成熟。
Biomed Res Int. 2019 Dec 28;2019:6051870. doi: 10.1155/2019/6051870. eCollection 2019.
4
Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics.利用微流控技术和分子基因组学发现的具有高亲和力的罕见鼠抗 PD-1 抗体,可用于检查点阻断。
MAbs. 2017 Nov/Dec;9(8):1270-1281. doi: 10.1080/19420862.2017.1371386. Epub 2017 Aug 28.
5
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.癌症免疫检查点阻断的耐药机制:肿瘤内在和外在因素。
Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001.
6
Rationale for anti-OX40 cancer immunotherapy.抗OX40癌症免疫疗法的原理。
Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30.
7
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.TIGIT:癌症免疫循环的关键抑制剂。
Trends Immunol. 2017 Jan;38(1):20-28. doi: 10.1016/j.it.2016.10.002. Epub 2016 Oct 25.
8
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.新型多特异性三抗体与已批准的免疫调节抗体组合的抗肿瘤疗效比较
Cancers (Basel). 2023 Nov 9;15(22):5345. doi: 10.3390/cancers15225345.
9
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.PD-1 阻断时机对 OX40 抗体联合免疫治疗的效果至关重要。
Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.
10
BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody.基于 BLI 的噬菌体展示功能分析有利于开发针对 PD-L1 的治疗性抗体。
Viruses. 2020 Jun 25;12(6):684. doi: 10.3390/v12060684.

引用本文的文献

1
High-throughput strategies for monoclonal antibody screening: advances and challenges.单克隆抗体筛选的高通量策略:进展与挑战
J Biol Eng. 2025 May 8;19(1):41. doi: 10.1186/s13036-025-00513-z.
2
A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.一种新型人抗FV单克隆抗体作为诊断和凝血抑制方法的潜在工具。
Int J Mol Sci. 2025 Mar 18;26(6):2721. doi: 10.3390/ijms26062721.
3
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

本文引用的文献

1
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells.长非编码 SINEUP RNA 促进 HEK293E 细胞中完全人源单克隆抗体的半稳定生产。
MAbs. 2018 Jul;10(5):730-737. doi: 10.1080/19420862.2018.1463945. Epub 2018 May 10.
2
Three Drugs Approved for Urothelial Carcinoma by FDA.美国食品药品监督管理局批准三种药物用于治疗尿路上皮癌。
Cancer Discov. 2017 Jul;7(7):659-660. doi: 10.1158/2159-8290.CD-NB2017-071. Epub 2017 May 25.
3
Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
靶向5T4、CD3和免疫检查点的三特异性三抗体比抗体治疗组合驱动更强的功能性T细胞反应。
Cell Death Discov. 2025 Feb 10;11(1):58. doi: 10.1038/s41420-025-02329-8.
4
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.新型多特异性三抗体与已批准的免疫调节抗体组合的抗肿瘤疗效比较
Cancers (Basel). 2023 Nov 9;15(22):5345. doi: 10.3390/cancers15225345.
5
Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy.噬菌体展示技术进展:为癌症免疫疗法定制抗体
Viruses. 2023 Sep 9;15(9):1903. doi: 10.3390/v15091903.
6
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.双歧杆菌对溶瘤腺病毒在黑色素瘤小鼠模型中的抗肿瘤疗效有影响。
iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20.
7
Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays.比较针对 SARS-CoV-2 刺突-RBD 的人源中和单克隆抗体 cilgavimab 和 tixagevimab 在中和和检测分析中对奥密克戎变异体的疗效。
Int J Mol Sci. 2023 Jun 13;24(12):10053. doi: 10.3390/ijms241210053.
8
Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.用于改进溶瘤病毒免疫疗法的系统生物学方法。
Cancers (Basel). 2023 Feb 17;15(4):1297. doi: 10.3390/cancers15041297.
9
Tim-3 Coordinates Macrophage-Trophoblast Crosstalk via Angiogenic Growth Factors to Promote Pregnancy Maintenance.Tim-3 通过血管生成生长因子协调巨噬细胞-滋养层细胞串扰,促进妊娠维持。
Int J Mol Sci. 2023 Jan 12;24(2):1538. doi: 10.3390/ijms24021538.
10
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC.抗程序性死亡配体1(PD-L1)和抗细胞毒性T淋巴细胞相关蛋白4(CTLA-4)单克隆抗体对三阴性乳腺癌不同淋巴细胞亚群作用的新见解
Cancers (Basel). 2022 Oct 27;14(21):5289. doi: 10.3390/cancers14215289.
阿替利珠单抗治疗局部晚期或转移性尿路上皮癌的药代动力学药物评估。
Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):225-232. doi: 10.1080/17425255.2017.1277204. Epub 2017 Jan 11.
4
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.肿瘤内注射一种CpG寡核苷酸可通过扩增多功能CD8 + T细胞来逆转对PD - 1阻断的抗性。
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249. doi: 10.1073/pnas.1608555113. Epub 2016 Oct 31.
5
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.伊匹单抗和纳武单抗联合免疫疗法的临床前开发:小鼠肿瘤模型、体外功能研究及食蟹猴毒理学
PLoS One. 2016 Sep 9;11(9):e0161779. doi: 10.1371/journal.pone.0161779. eCollection 2016.
6
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.癌症患者免疫检查点阻断相关不良事件:病例报告的系统评价
PLoS One. 2016 Jul 29;11(7):e0160221. doi: 10.1371/journal.pone.0160221. eCollection 2016.
7
Role of IL-2 in cancer immunotherapy.白细胞介素-2在癌症免疫治疗中的作用。
Oncoimmunology. 2016 Apr 25;5(6):e1163462. doi: 10.1080/2162402X.2016.1163462. eCollection 2016 Jun.
8
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.淋巴细胞激活基因-3、T细胞免疫球蛋白黏蛋白-3和T细胞免疫受体Ig和ITIM结构域:在免疫调节中具有特殊功能的共抑制受体。
Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001.
9
Antitumour actions of interferons: implications for cancer therapy.干扰素的抗肿瘤作用:对癌症治疗的启示。
Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14.
10
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.从基于高通量测序的噬菌体展示文库筛选中一步回收单链抗体片段(scFv)克隆,该文库针对表达天然闭合蛋白-1的细胞进行筛选。
Biomed Res Int. 2015;2015:703213. doi: 10.1155/2015/703213. Epub 2015 Nov 15.